1/123
Oncology Rat 15
Name | Mastery | Learn | Test | Matching | Spaced | Call with Kai |
|---|
No analytics yet
Send a link to your students to track their progress
Tender/Burning Vein
Swelling/Inflammation of the vein (ie. phlebitis)
Erythema
“Tightness” around the administration site
Itching
Medication that when extravasated may cause severe or irreversible tissue injury and necrosis at the infusion site and surrounding tissue
Initial: Like what is seen with irritant
Blistering
Pain around administration site
Severe: Necrosis/Tissue Breakdown
Specific drug
concentration
length of exposure
site of infiltration
Vesicant binds to DNA of healthy cells in surrounding tissues causing apoptosis/cell death leading to continued dispersion & uptake into adjacent health cells
Vesicant metabolized and neutralized in tissue causing less damage over time (gradual improvement)
Established Protocols/procedures
staff/patient education
check blood return
use central lines when appropriate
DNA-binding vesicants
Ex: doxorubicin
Non-DNA-binding vesicants
Ex: vincristine
What antidote is used for doxorubicin extravasation? What is the duration?
Dexrazoxane IV
Duration: 3 days
As soon as possible
within 6 hours of extravasation
& at least 15min. after cold compress
What antidote is used for Vinctristine extravasation? What is the duration?
Hyaluronidase SubQ/Intradermal
What is the administration timing for Hyaluronidase SubQ/Intradermal?
ASAP
Administered clockwise around the IV site in 5 separate injections
12 to 72 hours after chemo initiation
Potassium, phosphate, purines, pyrimidines
K+, PO43-, Purines & Pyrimidines
HYPERkalemia
HYPERphosphatemia
HYPOcalcemia
Excess phosphate binds serum calcium and precipitates
The ONLY electrolyte/metabolic abnormality that decreases
What is laboratory tumor lysis syndrome (TLS)?
2 or more metabolic abnormalities occurring
3 days before OR
7 days after treatment
What defines clinical tumor lysis syndrome (TLS)?
Laboratory TLS PLUS
1+ clinical implications (ex: increase in serum creatinine (SCr), cardiac dysrhythmia, seizure, or sudden death)
What is the metabolic abnormality associated with hypERkalemia in TLS?
K+ > 6mEq/L
can lead to cardiac dysrhythmias and sometimes sudden death
What is the metabolic abnormality associated with hypERphosphatemia in TLS?
PO43- > 4.5mg/dL
which can cause precipitation in blood and kidneys.
What is the metabolic abnormality associated with hypOcalcemia in TLS?
Corrected Ca2+ < 7mg/dL
which can lead to cardiac dysrhythmias, seizures, neuromuscular irritability, and tetany.
What is the metabolic abnormality associated with hypERuricemia in TLS?
Uric Acid > 8mg/dL
which can lead to acute renal failure from uric acid crystallization.
What is acute kidney injury (AKI) in the context of TLS?
Increase in SCr > 1.5x ULN OR
Oliguria (low OUP)
Identify major disease-related risk factors for TLS
High tumor burden
hematologic malignancies
Acute leukemias with high WBC
bulky lymphomas
bulky solid tumors
More tumor cells = more intracellular contents released during lysis
Dehydration
elevated uric acid
elevated LDH
baseline renal dysfunction
Venetoclax use
What does elevated LDH (lactate dehydrogenase) suggest in TLS risk assessment?
Allopurinol prophylaxis
ramp-up dosing
Maintain kidney flow
preserve urine output
keep labs normal at baseline
Normal saline
Maintains adequate urine output and promotes renal clearance
First-line xanthine oxidase inhibitor for TLS prophylaxis? Dose?
Allopurinol
300 mg PO daily to 300 mg PO twice daily
1 to 2 days before chemotherapy
High TLS risk
elevated baseline uric acid
unable to tolerate allopurinol
Converts uric acid into soluble allantoin (an Inactive and soluble metabolite of uric acid)
~4 hours
PTHrP secretion
osteolytic metastases
tumor calcitriol production
Increases bone resorption
increases renal calcium reabsorption
increases phosphate excretion
Lower phosphate levels are associated with higher serum calcium
Inverse relationship
Squamous cell carcinoma
renal cancer
breast cancer
Breast cancer with bone metastases
osteosarcoma
multiple myeloma
Constipation
Fatigue
NA
Polyuria
Lethargy
Confusion
Arrhythmias
Decreased consciousness
Bone pain
What is the general treatment approach for hypercalcemia of malignancy?
Treat the underlying cause FIRST
What is the mechanism of action (MOA) of IV fluids in hypercalcemia treatment?
Promotes renal calcium excretion and maintains urine output (UOP).
What is the first-line IV fluid used in treating hypercalcemia?
Normal saline (NS).
What role do loop diuretics play in hypercalcemia treatment?
May enhance calcium excretion if the patient is euvolemic.
What is the first-line IV bisphosphonate for hypercalcemia?
Zoledronic acid (Zometa), administered at 4 mg IV x1.
How does zoledronic acid work in treating hypercalcemia?
Inhibits bone resorption by stopping osteoclastic function.
What is the onset time for zoledronic acid to take effect?
24 to 72 hours, with the option to repeat in one week.